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REASONS FOR CONTINUING OR DISCONTINUING OLANZAPINE IN 
THE TREATMENT OF SCHIZOPHRENIA FROM PATIENTS’ AND 
CLINICIANS’ PERSPECTIVES
Chen J1, Ascher-Svanum H1, Case MG1, Nyhuis A1, Faries D1, Phillips G1, Perkins DO2, 
Hoffmann VP3
1Eli Lilly and Company, Indianapolis, IN, USA, 2University of North Carolina School of 
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OBJECTIVES: To identify the reasons for continuation or discontinuation of olan-
zapine in the treatment of schizophrenia from the patients’ and their clinicians’ per-
spectives. METHODS: Two measures were previously developed to assess the 
Reasons for Antipsychotic Discontinuation/Continuation (RAD), one from the 
patient’s perspective (RAD-I) and the other from patient’s clinician’s perspective 
(RAD-Q). These measures were administered to 199 outpatients with schizophrenia 
and their clinicians, participants in a 22-week open-label study of olanzapine. Reasons 
for continuation and for discontinuation of olanzapine were rated on a 5-point scale 
from “primary reason” to “not a reason.” The single most important reason was also 
identiﬁed. The top “primary reasons” for continuation and for discontinuation of 
olanzapine were identiﬁed. Levels of concordance between patients’ and clinicians’ 
reasons were assessed. RESULTS: Patients and clinicians have identiﬁed several 
primary reasons for continuation or discontinuation of olanzapine (2.3 to 8.5 reasons, 
on average). The top “primary reasons” for continuation on olanzapine were patient’s 
perception of improvement, improvement of positive symptoms, and improved func-
tioning. Study discontinuation rate was relatively low, and only a few of the discon-
tinued participants reported reasons for medication discontinuing. The top “primary 
reasons” for discontinuing olanzapine were: insufﬁcient improvement or worsening 
of positive symptoms, adverse events, and insufﬁcient improvement or worsening of 
negative symptoms. A high level of concordance was observed between patients’ and 
clinicians’ ratings. CONCLUSIONS: Medication efﬁcacy, especially for positive 
symptoms, appears to be the core driver of continuation on olanzapine and of its 
infrequent discontinuation. Reasons for medication discontinuation differ somewhat 
from reasons for continuation, with a high level of concordance between patients’ and 
clinicians’ perspectives.
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REFUSAL OF ANCILLARY SUPPORT SERVICES EARLY IN TREATMENT 
PREDICTS SIX MONTH OUTCOMES AMONG BUPRENORPHINE-
MEDICATION ASSISTED TREATMENT PATIENTS
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OBJECTIVES: Multiple treatment options exist for chemical dependence patients 
including medication, counseling, and self-help groups. Prior research indicates that 
outcomes may be affected by choices patients make early in treatment. The purpose 
of this study was to examine patient differences among those who chose to participate 
in an ancillary patient support program early in opioid dependence (OD) treatment 
compared to those who chose not to. METHODS: OD patients new to B-MAT (N = 
1426) were randomized to receive B-MAT plus a patient support program (experi-
mental group, n = 987) or B-MAT alone (standard care, n = 439). The experimental 
group was divided into 2 groups based on patient choice: 1. refused to participate in 
the intervention (n = 336); 2. agreed to participate (n = 651). Subjects completed the 
Addiction Severity Index (ASI) at baseline, 1, 2, 3, and 6 months post-enrollment. The 
ASI is a semi-structured interview designed to measure problem severity in 7 functional 
areas known to be affected by alcohol and drug dependence. RESULTS: At month 
six, subjects who refused the intervention were less likely to be compliant with B-MAT 
(51.4%) compared to both the accepted intervention group (70.1%) and the standard 
care group (64.7%; χ2(2, n = 1062) = 25.24, p < .001). Further, at baseline, those 
who refused the intervention had lower legal, psychiatric, and family composite scores, 
which indicates lower problem severity in these areas, (p’s < .05) compared to experi-
mental cases who agreed to participate. CONCLUSIONS: Subjects who refused the 
intervention reported the lowest rate of B-MAT compliance at month six making 
refusal a potential triage indicator. However, as a group, refusers also reported lower 
problem severity in several functional areas at baseline compared to those who agreed 
to participate. Refusal of ancillary services alone is not an adequate triage indicator 
as refusals are heterogeneous in problem severity make-up.
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A LONGITUDINAL ANALYSIS OF THE EFFECT OF BUPRENORPHINE-
MEDICATION ASSISTED TREATMENT (B-MAT) AND A STRUCTURED 
PATIENT SUPPORT PROGRAM ON B-MAT ADHERENCE IN A 
NATIONAL SAMPLE OF OPIOID DEPENDENT PATIENTS
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OBJECTIVES: The purpose of this study was to examine the longitudinal effect of 
buprenorphine-medication assisted treatment (B-MAT), combined with a patient 
support program, on medication adherence in a sample of opioid dependent patients. 
Its effect on drug abuse will also be explored. METHODS: OD patients new to 
B-MAT (N = 410) were randomized to receive B-MAT plus a patient support program 
(experimental group, n = 249) or B-MAT alone (standard care, n = 161). All patients 
completed the Addiction Severity Index (ASI) at baseline, 1, 2, 3, and 6 months post-
enrollment. The ASI is a semi-structured interview designed to measure problem 
severity in 7 functional areas known to be affected by alcohol and drug dependence. 
A repeated measures ANOVA was used to detect group, time and interaction effects 
for compliance with B-MAT. RESULTS: One year follow-up data will be presented 
in the poster; however, only 6 month data were available at the time of submission. 
The intervention group reported taking their medication on more days than controls 
F(1408) = 4.48; p < 0.05). A signiﬁcant time effect was also observed F(3, 1224) = 
36.9, p < 0.001), with subjects as a whole taking their medication on less days as the 
study progressed. The signiﬁcant time x group interaction indicated that subjects in 
the control group took their medication on less days over the course of the study 
compared to the intervention group (F(3, 1224) = 2.34, p < 0.10). Greater involvement 
in the intervention also led to reductions in opioid abuse (p < 0.05). CONCLUSIONS: 
The patient support program seemed to improve the number of days OD patients took 
their medication and reduced the likelihood of abusing drugs. Supplementing B-MAT 
with a structured compliance-enhancement program may be an effective way to 
improve adherence with medication in a sample of OD patients.
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THE EFFECT OF A TELEPHONIC PATIENT SUPPORT PROGRAM ON 
TREATMENT OUTCOMES AMONG A SAMPLE OF OPIOID DEPENDNCE 
PATIENTS: ONE YEAR FOLLOW-UP
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OBJECTIVES: Buprenorphine-medication assisted treatment (B-MAT) is clinically 
effective for opioid dependence (OD). However, participation in ancillary treatment 
activities may enhance medication compliance, thereby improving treatment out-
comes. The purpose of the present study was to investigate the effect of a telephonic 
patient compliance-enhancement program on B-MAT compliance in a sample of OD 
patients after one year in treatment. METHODS: OD patients new to B-MAT (N = 
1426) were randomized to receive B-MAT plus the telephonic patient support program 
(intervention group) or B-MAT alone (standard care group). Patients completed the 
Addiction Severity Index (ASI) at the time of enrollment and at 5 follow-up periods 
over the course of one year. The ASI is a semi-structured interview designed to measure 
problem severity in 7 functional areas known to be affected by alcohol and drug 
dependence. RESULTS: One year follow-up data will be presented in the poster; 
however, only 6 month data were available at the time of submission. The intervention 
group was signiﬁcantly more compliant with B-MAT than the standard care group 
(73.3% vs. 64.7%, χ2 = 6.43, p = 0.01). Furthermore, greater involvement in the 
intervention led to a reduction in the use of injection and prescription opioids (p’s < 
0.05). CONCLUSIONS: The compliance-enhancement intervention improved adher-
ence to B-MAT and patient treatment including abuse of opioids. Supplementing 
B-MAT with a structured, telephonic compliance-enhancement program is an effective 
way to improve compliance with medication as well as patient outcomes.
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OBJECTIVES: Studies consistently show high relapse rates (25%–35%) among chemi-
cal dependence patients. Relapse is especially problematic for patients diagnosed with 
opioid dependence (OD), which has often been characterized as a chronic relapsing 
disorder. The purpose of the present study was to examine the effect of compliance 
with buprenorphine-medication assisted treatment (B-MAT) on relapse among a 
sample of opioid dependent patients. METHODS: OD patients new to B-MAT (N = 
554) completed the Addiction Severity Index (ASI) at baseline, 1, 2, 3, and 6 months 
post-enrollment. The ASI is a semi-structured interview designed to measure problem 
severity in 7 functional areas known to be affected by alcohol and drug dependence. 
One year follow-up data will be presented in the poster; however, only 6 month data 
were available at the time of submission. Compliance with B-MAT was deﬁned as 
taking medication on at least 80% of the days over the past month. Relapse was 
deﬁned as use of opioids, including heroin, methadone, or pharmaceutical opioids, 
after an initial period of no use. RESULTS: Patients who were compliant with B-MAT 
were signiﬁcantly less likely to relapse compared to subjects who were non-compliant 
with B-MAT (24.8% vs. 57.8%, χ2(1, n = 493) = 37.49, p < 0.001). Differences in 
baseline characteristics between the compliance groups and the relapse groups were 
also revealing. Patients who relapsed had signiﬁcantly higher baseline medical, legal, 
psychiatric, and family composites scores compared to those who did not relapse (p’s 
< 0.05), indicating greater problem severity in these areas. CONCLUSIONS: Compli-
ance with B-MAT for six months seems to reduce the likelihood of relapse in OD 
patients. Difference in patient characteristics may be used to help providers identify 
patients who need higher levels of care to avoid relapse. Future studies should examine 
relapse rates in patients who have successfully tapered off B-MAT.
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ISSUES IN THE USE OF THE HOSPITAL ANXIETY AND DEPRESSION 
SCALE IN AN ALCOHOL-DEPENDENT POPULATION
McPherson A, Martin CR
University of the West of Scotland, Ayr, UK
OBJECTIVES: To evaluate the psychometric properties of the Hospital Anxiety and 
Depression Scale (HADS) in selected research to ascertain the suitability of this tool 
for screening for anxiety and depression in an alcohol-dependent population. 
METHODS: Narrative review. RESULTS: Of the 529 articles initially evaluated, 
selected studies included 28 studies used to evaluate the factor analysis of the HADS, 
